Vor Biopharma VOR Restricted cash equivalents included in Other long-term assets
Restricted cash equivalents included in Other long-term assets at other companies
Other financials
Where this comes from
Reported directly by Vor Biopharma in its filing.
Tagged under the XBRL concept us-gaap:RestrictedCashEquivalentsNoncurrent.
The official record: Vor Biopharma’s 10-Q, filed May 13, 2026, on SEC EDGAR. View the filing →
Ask your AI about Vor Biopharma's restricted cash equivalents included in other long-term assets.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Vor Biopharma's restricted cash equivalents included in other long-term assets?
- Vor Biopharma (VOR) reported restricted cash equivalents included in other long-term assets of $168K in Q1 2026.
- How has Vor Biopharma's restricted cash equivalents included in other long-term assets changed year-over-year?
- Vor Biopharma's restricted cash equivalents included in other long-term assets decreased by 93.0% year-over-year, from $2.41M to $168K.
- What is the long-term trend for Vor Biopharma's restricted cash equivalents included in other long-term assets?
- Over 5 years (2020 to 2025), Vor Biopharma's restricted cash equivalents included in other long-term assets has grown at a -36.0% compound annual growth rate (CAGR), from $1.56M to $168K.
- What does restricted cash equivalents included in other long-term assets mean?
- This represents cash and cash equivalent balances that are legally restricted from withdrawal or use for general corporate purposes for a period exceeding one year. These funds are typically held as collateral for long-term lease agreements, debt obligations, or specific regulatory requirements. Monitoring this balance is essential for assessing the company's true liquidity and the portion of assets unavailable to fund ongoing clinical research and development operations.